Any feedback?
Information on EC 3.4.23.16 - HIV-1 retropepsin
for references in articles please use BRENDA:EC3.4.23.16Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
3.4.23.16 HIV-1 retropepsinSpecify your search results
Word Map
- 3.4.23.16
-
antiretroviral
- ritonavir
- transcriptase
- saquinavir
- indinavir
- nelfinavir
-
hiv-infected
- lopinavir
- polyproteins
- flap
- darunavir
- amprenavir
-
drug-resistant
-
anti-hiv
- atazanavir
-
virological
-
haart
- gag-pol
-
peptidomimetic
- virion
- p-glycoprotein
- lipodystrophy
-
non-nucleoside
-
integrase
-
cross-resistance
- isostere
-
nonpeptidic
- zidovudine
- nevirapine
- virus-1
- tipranavir
- cyp3a4
-
nnrti
-
drug-drug
-
treatment-experienced
- lamivudine
- didanosine
-
ritonavir-boosted
-
autoprocessing
- efavirenz
-
protease-inhibitor
- stavudine
-
treatment-naive
- analysis
- raltegravir
- zalcitabine
-
plasmepsins
-
antiretroviral-naive
-
pi-based
- pharmacology
- drug development
- medicine
-
hiv-rna
-
lipoatrophy
The enzyme appears in viruses and cellular organisms
Reaction Schemes
specific for a P1 residue that is hydrophobic, and P1' variable, but often Pro
Synonyms
hiv-1 protease, hiv protease, hiv-1 pr, hiv pr, human immunodeficiency virus protease, hiv-1 proteinase, human immunodeficiency virus type 1 protease, gag protease, hivpr, hiv-1pr, 
more
topPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
Gag protease
-
-
-
-
HIV aspartyl protease
-
-
-
-
HIV-1 protease
-
-
-
-
HIV-1 proteinase
-
-
-
-
human immunodeficiency virus type 1 protease
-
-
-
-
retropepsin
-
-
-
-
retroproteinase
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
hydrolysis of peptide bond
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
144114-21-6
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
4,5-anhydro-1,2,6-trideoxy-2-[[N-(phenoxyacetyl)-L-valyl]amino]-1,6-diphenyl-D-galactitol
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Achlorhydria
Meal Effects Confound Attempts to Counteract Rabeprazole-Induced Hypochlorhydria Decreases in Atazanavir Absorption.
Acquired Immunodeficiency Syndrome
A C2 symmetry-based HIV protease inhibitor, A77003, irreversibly inhibits infectivity of HIV-1 in vitro.
Acquired Immunodeficiency Syndrome
A computational study of CYP3A4 mediated drug interaction profiles for anti-HIV drugs.
Acquired Immunodeficiency Syndrome
A conserved hydrogen-bonding network of P2 bis-tetrahydrofuran-containing HIV-1 protease inhibitors (PIs) with a protease active-site amino acid backbone aids in their activity against PI-resistant HIV.
Acquired Immunodeficiency Syndrome
A Convergent, Scalable Synthesis of HIV Protease Inhibitor PNU-140690.
Acquired Immunodeficiency Syndrome
A formulation for correlating properties of peptides and its application to predicting human immunodeficiency virus protease-cleavable sites in proteins.
Acquired Immunodeficiency Syndrome
A novel nonpeptide HIV-1 protease inhibitor: elucidation of the binding mode and its application in the design of related analogs.
Acquired Immunodeficiency Syndrome
A novel transglutaminase-catalyzed posttranslational modification of HIV-1 aspartyl protease.
Acquired Immunodeficiency Syndrome
A pharmacokinetic-pharmacodynamic model of chemotherapy of human immunodeficiency virus infection that relates development of drug resistance to treatment intensity.
Acquired Immunodeficiency Syndrome
A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine.
Acquired Immunodeficiency Syndrome
A phase I trial of the pharmacokinetics, toxicity, and activity of KNI-272, an inhibitor of HIV-1 protease, in patients with AIDS or symptomatic HIV infection.
Acquired Immunodeficiency Syndrome
A vector projection approach to predicting HIV protease cleavage sites in proteins.
Acquired Immunodeficiency Syndrome
A vectorized sequence-coupling model for predicting HIV protease cleavage sites in proteins.
Acquired Immunodeficiency Syndrome
Accessory mutations balance the marginal stability of the HIV-1 protease in drug resistance.
Acquired Immunodeficiency Syndrome
Acipimox, an Inhibitor of Lipolysis, Attenuates Atherogenesis in LDLR-Null Mice Treated With HIV Protease Inhibitor Ritonavir.
Acquired Immunodeficiency Syndrome
Agaritine and its derivatives are potential inhibitors against HIV proteases.
Acquired Immunodeficiency Syndrome
alpha 2-Macroglobulin is cleaved by HIV-1 protease in the bait region but not in the C-terminal inter-domain region.
Acquired Immunodeficiency Syndrome
An alternate-subsite-coupled model for predicting HIV protease cleavage sites in proteins.
Acquired Immunodeficiency Syndrome
An alternative strategy for inhibiting multidrug-resistant mutants of the dimeric HIV-1 protease by targeting the subunit interface.
Acquired Immunodeficiency Syndrome
An efficient procedure for the expression and purification of HIV-1 protease from inclusion bodies.
Acquired Immunodeficiency Syndrome
An Efficient Synthesis of a Hydroxyethylamine (HEA) Isostere and Its ?-Aminophosphonate and Phosphoramidate Derivatives as Potential Anti-HIV Agents.
Acquired Immunodeficiency Syndrome
An ultrasensitive human immunodeficiency virus type 1 protease radioimmuno rate assay with a potential for monitoring blood levels of protease inhibitors in acquired immunodeficiency disease syndrome patients.
Acquired Immunodeficiency Syndrome
Anti-apoptotic effect of HIV protease inhibitors via direct inhibition of calpain.
Acquired Immunodeficiency Syndrome
Antibody response to human immunodeficiency virus type 1 protease according to risk group and disease stage.
Acquired Immunodeficiency Syndrome
Artificial neural network method for predicting HIV protease cleavage sites in protein.
Acquired Immunodeficiency Syndrome
Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir.
Acquired Immunodeficiency Syndrome
Candida proteases and their inhibition: prospects for antifungal therapy.
Acquired Immunodeficiency Syndrome
Catalytic water co-existing with a product peptide in the active site of HIV-1 protease revealed by X-ray structure analysis.
Acquired Immunodeficiency Syndrome
Caught in the Act: the 1.5 A resolution crystal structures of the HIV-1 protease and the I54V mutant reveal a tetrahedral reaction intermediate.
Acquired Immunodeficiency Syndrome
Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor.
Acquired Immunodeficiency Syndrome
Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease.
Acquired Immunodeficiency Syndrome
Combination therapy with zidovudine, didanosine and saquinavir.
Acquired Immunodeficiency Syndrome
Comparative studies on inhibitors of HIV protease: a target for drug design.
Acquired Immunodeficiency Syndrome
Comparative studies on retroviral proteases: substrate specificity.
Acquired Immunodeficiency Syndrome
Computational simulations of HIV-1 proteases-multi-drug resistance due to nonactive site mutation L90M.
Acquired Immunodeficiency Syndrome
Computational studies of darunavir into HIV-1 protease and DMPC bilayer: necessary conditions for effective binding and the role of the flaps.
Acquired Immunodeficiency Syndrome
Computational study of protein specificity: the molecular basis of HIV-1 protease drug resistance.
Acquired Immunodeficiency Syndrome
Conformational Motions of HIV-1 Protease Identified Using Reversible Digitally Filtered Molecular Dynamics.
Acquired Immunodeficiency Syndrome
Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance.
Acquired Immunodeficiency Syndrome
Crystal structure of HIV-1 protease in situ product complex and observation of a low-barrier hydrogen bond between catalytic aspartates.
Acquired Immunodeficiency Syndrome
Crystal structure of human T cell leukemia virus protease, a novel target for anticancer drug design.
Acquired Immunodeficiency Syndrome
Crystal Structures of Highly Constrained Substrate and Hydrolysis Products Bound to HIV-1 Protease. Implications for the Catalytic Mechanism.
Acquired Immunodeficiency Syndrome
Crystal structures of HIV-2 protease in complex with inhibitors containing the hydroxyethylamine dipeptide isostere.
Acquired Immunodeficiency Syndrome
Decomposing the energetic impact of drug-resistant mutations: the example of HIV-1 protease-DRV binding.
Acquired Immunodeficiency Syndrome
Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors.
Acquired Immunodeficiency Syndrome
Design of potent aspartic protease inhibitors to treat various diseases.
Acquired Immunodeficiency Syndrome
Design, asymmetric synthesis, and evaluation of pseudosymmetric sulfoximine inhibitors against HIV-1 protease.
Acquired Immunodeficiency Syndrome
Directed evolution of toluene dioxygenase from Pseudomonas putida for improved selectivity toward cis-indandiol during indene bioconversion.
Acquired Immunodeficiency Syndrome
Diversity-Oriented Synthesis of Diol-Based Peptidomimetics as Potential HIV Protease Inhibitors and Antitumor Agents.
Acquired Immunodeficiency Syndrome
Drug resistance conferred by mutations outside the active site through alterations in the dynamic and structural ensemble of HIV-1 protease.
Acquired Immunodeficiency Syndrome
Drug resistance in HIV-1 protease: Flexibility-assisted mechanism of compensatory mutations.
Acquired Immunodeficiency Syndrome
Drug Resistance of HIV-1 Protease Against JE-2147: I47V Mutation Investigated by Molecular Dynamics Simulation.
Acquired Immunodeficiency Syndrome
Drug-resistant HIV-1 protease regains functional dynamics through cleavage site coevolution.
Acquired Immunodeficiency Syndrome
Dual inhibitors for aspartic proteases HIV-1 PR and renin: advancements in AIDS-hypertension-diabetes linkage via molecular dynamics, inhibition assays, and binding free energy calculations.
Acquired Immunodeficiency Syndrome
Dynamic and Electrostatic Effects on the Reaction Catalyzed by HIV-1 Protease.
Acquired Immunodeficiency Syndrome
Effect of a human immunodeficiency virus protease inhibitor on human monocyte function.
Acquired Immunodeficiency Syndrome
Effect of Biomolecular Conformation on Docking Simulation: A Case Study on a Potent HIV-1 Protease Inhibitor.
Acquired Immunodeficiency Syndrome
Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites.
Acquired Immunodeficiency Syndrome
Electrostatics Plays a Crucial Role in HIV-1 Protease Substrate Binding, Drugs Fail to Take Advantage.
Acquired Immunodeficiency Syndrome
Enzymatic activity of a synthetic 99 residue protein corresponding to the putative HIV-1 protease.
Acquired Immunodeficiency Syndrome
Exploring the concerted mechanistic pathway for HIV-1 PR-substrate revealed by umbrella sampling simulation.
Acquired Immunodeficiency Syndrome
Expression in Escherichia coli of the AIDS virus aspartic protease through a protein fusion.
Acquired Immunodeficiency Syndrome
From recognition to reaction mechanism: an overview on the interactions between HIV-1 protease and its natural targets.
Acquired Immunodeficiency Syndrome
HIV protease as an inhibitor target for the treatment of AIDS.
Acquired Immunodeficiency Syndrome
HIV protease inhibition: limited recent progress and advances in understanding current pitfalls.
Acquired Immunodeficiency Syndrome
HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833.
Acquired Immunodeficiency Syndrome
HIV protease inhibitor therapy reverses neutrophil apoptosis in AIDS patients by direct calpain inhibition.
Acquired Immunodeficiency Syndrome
HIV protease inhibitors block adipogenesis and increase lipolysis in vitro.
Acquired Immunodeficiency Syndrome
HIV protease inhibitors stimulate hepatic triglyceride synthesis.
Acquired Immunodeficiency Syndrome
HIV protease inhibitory bis-benzamide cyclic ureas: a quantitative structure-activity relationship analysis.
Acquired Immunodeficiency Syndrome
HIV-1 protease inhibitor ritonavir modulates susceptibility to apoptosis of uninfected T cells.
Acquired Immunodeficiency Syndrome
HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study.
Acquired Immunodeficiency Syndrome
HIV-1 protease inhibitors: development, status, and potential role in the treatment of AIDS.
Acquired Immunodeficiency Syndrome
HIV-1 protease: mutagenesis of asparagine 88 indicates a domain required for dimer formation.
Acquired Immunodeficiency Syndrome
HIV-1 Protease: Structural Perspectives on Drug Resistance.
Acquired Immunodeficiency Syndrome
How an inhibitor of the HIV-I protease modulates proteasome activity.
Acquired Immunodeficiency Syndrome
Human immunodeficiency virus protease inhibitors. From drug design to clinical studies.
Acquired Immunodeficiency Syndrome
Hydroxyquinones are competitive non-peptide inhibitors of HIV-1 proteinase.
Acquired Immunodeficiency Syndrome
Identification and characterization of a novel retroviral-like aspartic protease specifically expressed in human epidermis.
Acquired Immunodeficiency Syndrome
Identifying the Molecular Mechanics and Binding Dynamics Characteristics of Potent Inhibitors to HIV-1 Protease.
Acquired Immunodeficiency Syndrome
Impeded progression of Friend disease in mice by an inhibitor of retroviral proteases.
Acquired Immunodeficiency Syndrome
In vitro selection and characterization of VX-478 resistant HIV-1 variants.
Acquired Immunodeficiency Syndrome
In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.
Acquired Immunodeficiency Syndrome
Increasing survival in AIDS patients with cytomegalovirus retinitis treated with combination antiretroviral therapy including HIV protease inhibitors.
Acquired Immunodeficiency Syndrome
Inferring within-patient HIV-1 evolutionary dynamics under anti-HIV therapy using serial virus samples with vSPA.
Acquired Immunodeficiency Syndrome
Inhibition of adipocyte differentiation by HIV protease inhibitors.
Acquired Immunodeficiency Syndrome
Inhibitors of aspartic proteases in human diseases: molecular modeling comes of age.
Acquired Immunodeficiency Syndrome
Insight into analysis of interactions of saquinavir with HIV-1 protease in comparison between the wild-type and G48V and G48V/L90M mutants based on QM and QM/MM calculations.
Acquired Immunodeficiency Syndrome
Insight into binding mechanisms of inhibitors MKP56, MKP73, MKP86, and MKP97 to HIV-1 protease by using molecular dynamics simulation.
Acquired Immunodeficiency Syndrome
Interpretation of protein/ligand crystal structure using QM/MM calculations: case of HIV-1 protease/metallacarborane complex.
Acquired Immunodeficiency Syndrome
Intracellular expression of human immunodeficiency virus type 1 (HIV-1) protease variants inhibits replication of wild-type and protease inhibitor-resistant HIV-1 strains in human T-cell lines.
Acquired Immunodeficiency Syndrome
Involvement of cytochromes p450 in drug-drug interactions: an overview.
Acquired Immunodeficiency Syndrome
Ion specific effects of alkali cations on the catalytic activity of HIV-1 protease.
Acquired Immunodeficiency Syndrome
Joint X-ray/Neutron Crystallographic Study of HIV-1 Protease with Clinical Inhibitor Amprenavir: Insights for Drug Design.
Acquired Immunodeficiency Syndrome
Mechanism of drug resistance revealed by the crystal structure of the unliganded HIV-1 protease with F53L mutation.
Acquired Immunodeficiency Syndrome
Modified solvent accessibility free energy prediction analysis of cyclic urea inhibitors binding to the HIV-1 protease.
Acquired Immunodeficiency Syndrome
Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformationally flexible docking by evolutionary programming.
Acquired Immunodeficiency Syndrome
Mutations and polymorphisms associated with antiretroviral drugs in HIV-1C-infected African patients.
Acquired Immunodeficiency Syndrome
New insights into the in silico prediction of HIV protease resistance to nelfinavir.
Acquired Immunodeficiency Syndrome
Non-active site changes elicit broad-based cross-resistance of the HIV-1 protease to inhibitors.
Acquired Immunodeficiency Syndrome
Noninvasive high-throughput single-cell analysis of HIV protease activity using ratiometric flow cytometry.
Acquired Immunodeficiency Syndrome
Observation of a tetrahedral reaction intermediate in the HIV-1 protease-substrate complex.
Acquired Immunodeficiency Syndrome
Off-Target-Based Design of Selective HIV-1 PROTEASE Inhibitors.
Acquired Immunodeficiency Syndrome
Optimization of P1-P3 groups in symmetric and asymmetric HIV-1 protease inhibitors.
Acquired Immunodeficiency Syndrome
Origin of Decrease in Potency of Darunavir and Two Related Antiviral Inhibitors against HIV-2 Compared to HIV-1 Protease.
Acquired Immunodeficiency Syndrome
pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs.
Acquired Immunodeficiency Syndrome
Pharmacokinetic interactions between HIV-1 protease inhibitors in rats: study on combinations of two kinds of HIV-1 protease inhibitors.
Acquired Immunodeficiency Syndrome
Pharmacokinetics of HIV protease inhibitor DMP 323 in rats and dogs.
Acquired Immunodeficiency Syndrome
Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis.
Acquired Immunodeficiency Syndrome
Predicting cleavability of peptide sequences by HIV protease via correlation-angle approach.
Acquired Immunodeficiency Syndrome
Prediction of HIV-1 protease cleavage site using a combination of sequence, structural, and physicochemical features.
Acquired Immunodeficiency Syndrome
Protease inhibitor therapy is associated with markedly prolonged time to relapse and improved survival in AIDS patients with cytomegalovirus retinitis.
Acquired Immunodeficiency Syndrome
Protease Inhibitors for the Treatment of HIV/AIDS: Recent Advances and Future Challenges.
Acquired Immunodeficiency Syndrome
Protection against experimental autoimmune encephalomyelitis by a proteasome modulator.
Acquired Immunodeficiency Syndrome
Protein conformational dynamics in the mechanism of HIV-1 protease catalysis.
Acquired Immunodeficiency Syndrome
Proton transfer and drug binding details revealed in neutron diffraction studies of wild-type and drug resistant HIV-1 protease.
Acquired Immunodeficiency Syndrome
Purification and biochemical characterization of recombinant simian immunodeficiency virus protease and comparison to human immunodeficiency virus type 1 protease.
Acquired Immunodeficiency Syndrome
Purification and characterization of naturally occurring HIV-1 (South African subtype C) protease mutants from inclusion bodies.
Acquired Immunodeficiency Syndrome
Quality assessment for therapeutic drug monitoring in AIDS Clinical Trials Group (ACTG 5146): a multicenter clinical trial.
Acquired Immunodeficiency Syndrome
Rapid screening for HIV-1 protease inhibitor leads through X-ray diffraction.
Acquired Immunodeficiency Syndrome
Rational design and Structure-Activity relationship of coumarin derivatives effective on HIV-1 protease and partially on HIV-1 reverse transcriptase.
Acquired Immunodeficiency Syndrome
Recent Developments of Peptidomimetic HIV-1 Protease Inhibitors.
Acquired Immunodeficiency Syndrome
Regression of cytomegalovirus retinitis associated with protease-inhibitor treatment in patients with AIDS.
Acquired Immunodeficiency Syndrome
Relative differences in the binding free energies of human immunodeficiency virus 1 protease inhibitors: a thermodynamic cycle-perturbation approach.
Acquired Immunodeficiency Syndrome
Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group.
Acquired Immunodeficiency Syndrome
Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor.
Acquired Immunodeficiency Syndrome
Second generation HIV protease inhibitors against resistant virus.
Acquired Immunodeficiency Syndrome
Secreted aspartic proteases as virulence factors of Candida species.
Acquired Immunodeficiency Syndrome
Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor.
Acquired Immunodeficiency Syndrome
Selective and facile assay of HIV protease activity by a novel fluorogenic reaction.
Acquired Immunodeficiency Syndrome
Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism.
Acquired Immunodeficiency Syndrome
Sex-dependent pharmacokinetics of indinavir: in vivo and in vitro evidence.
Acquired Immunodeficiency Syndrome
Solubilization of a tripeptide HIV protease inhibitor using a combination of ionization and complexation with chemically modified cyclodextrins.
Acquired Immunodeficiency Syndrome
Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor.
Acquired Immunodeficiency Syndrome
Stimulation of vitamin A(1) acid signaling by the HIV protease inhibitor indinavir.
Acquired Immunodeficiency Syndrome
Structural Biology and the Design of New Therapeutics: From HIV and Cancer to Mycobacterial Infections: A Paper Dedicated to John Kendrew.
Acquired Immunodeficiency Syndrome
Structural implications of drug-resistant mutants of HIV-1 protease: high-resolution crystal structures of the mutant protease/substrate analogue complexes.
Acquired Immunodeficiency Syndrome
Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine.
Acquired Immunodeficiency Syndrome
Structure-based design of symmetric inhibitors of HIV-1 protease.
Acquired Immunodeficiency Syndrome
Structure-based discovery of Tipranavir disodium (PNU-140690E): a potent, orally bioavailable, nonpeptidic HIV protease inhibitor.
Acquired Immunodeficiency Syndrome
Structure-based prediction of potential binding and nonbinding peptides to HIV-1 protease.
Acquired Immunodeficiency Syndrome
Structure-guided, target-based drug discovery - exploiting genome information from HIV to mycobacterial infections.
Acquired Immunodeficiency Syndrome
Studies on the specificity of HIV protease: an application of Markov chain theory.
Acquired Immunodeficiency Syndrome
Study of the Conformational Dynamics of the Catalytic Loop of WT and G140A/G149A HIV-1 Integrase Core Domain Using Reversible Digitally Filtered Molecular Dynamics.
Acquired Immunodeficiency Syndrome
Substrate recognition in HIV-1 protease: a computational study.
Acquired Immunodeficiency Syndrome
Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes.
Acquired Immunodeficiency Syndrome
Support Vector Machines for predicting HIV protease cleavage sites in protein.
Acquired Immunodeficiency Syndrome
Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacy.
Acquired Immunodeficiency Syndrome
Synthesis and biological activity of potent HIV-1 protease inhibitors based on Phe-Pro dihydroxyethylene isosteres.
Acquired Immunodeficiency Syndrome
Targeting HIV protease: from peptidomimetics to non-peptide inhibitors.
Acquired Immunodeficiency Syndrome
The 3-D structure of HIV-1 proteinase and the design of antiviral agents for the treatment of AIDS.
Acquired Immunodeficiency Syndrome
The evaluation of non-viral substrates of the HIV protease as leads in the design of inhibitors for AIDS therapy.
Acquired Immunodeficiency Syndrome
The folding and dimerization of HIV-1 protease: evidence for a stable monomer from simulations.
Acquired Immunodeficiency Syndrome
The molecular evolution of HIV-1 protease simulated at atomic detail.
Acquired Immunodeficiency Syndrome
The protease inhibitor atazanavir blocks hERG K(+) channels expressed in HEK293 cells and obstructs hERG protein transport to cell membrane.
Acquired Immunodeficiency Syndrome
The use of experimental structures to model protein dynamics.
Acquired Immunodeficiency Syndrome
Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials.
Acquired Immunodeficiency Syndrome
Urea-dependent unfolding of HIV-1 protease studied by circular dichroism and small-angle X-ray scattering.
Acquired Immunodeficiency Syndrome
Validation of simultaneous quantitative method of HIV protease inhibitors atazanavir, darunavir and ritonavir in human plasma by UPLC-MS/MS.
Acquired Immunodeficiency Syndrome
Variable context Markov chains for HIV protease cleavage site prediction.
Acquired Immunodeficiency Syndrome
Visualizing Tetrahedral Oxyanion Bound in HIV-1 Protease Using Neutrons: Implications for the Catalytic Mechanism and Drug Design.
Acquired Immunodeficiency Syndrome
Whiskers-less HIV-protease: a possible Way for HIV-1 deactivation.
Acquired Immunodeficiency Syndrome
X-ray crystallographic studies of a series of penicillin-derived asymmetric inhibitors of HIV-1 protease.
Acquired Immunodeficiency Syndrome
X-ray structure of HIV-1 protease in situ product complex.
Acquired Immunodeficiency Syndrome
[An important point of attach in AIDS treatment. HIV protease inhibitors: state of the art]
Acquired Immunodeficiency Syndrome
[Approval of HIV protease inhibitors as the AIDS therapeutics of next generation]
Acquired Immunodeficiency Syndrome
[Development of anti-HIV agents based on chemical biology].
Acquired Immunodeficiency Syndrome
[Development of HIV protease inhibitors as anti AIDS drugs: molecular design based on substrate transition state]
Acquired Immunodeficiency Syndrome
[Molecular modeling in the battle against AIDS. Drugs design in the development of substrate-like HIV protease inhibitors]
Acute Coronary Syndrome
[Acute coronary syndromes in patients treated with HIV protease inhibitors]
Acute Kidney Injury
Acute renal failure due to indinavir crystalluria and nephrolithiasis: report of two cases.
Acute Lung Injury
The HIV protease inhibitor Saquinavir attenuates sepsis-induced acute lung injury and promotes M2 macrophage polarization via targeting matrix metalloproteinase-9.
AIDS Dementia Complex
HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833.
AIDS Dementia Complex
Induction of P-glycoprotein expression and activity by ritonavir in bovine brain microvessel endothelial cells.
AIDS-Related Opportunistic Infections
Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy.
Alzheimer Disease
Application of the O-N intramolecular acyl migration reaction in medicinal chemistry.
Alzheimer Disease
The Effect of HIV Protease Inhibitors on Amyloid-? Peptide Degradation and Synthesis in Human Cells and Alzheimer's Disease Animal Model.
Anemia, Hemolytic
Prevalence of clinically relevant UGT1A alleles and haplotypes in African populations.
Anosmia
Efficacy of local budesonide therapy in the management of persistent hyposmia in COVID-19 patients without signs of severity: A structured summary of a study protocol for a randomised controlled trial.
Arthralgia
Arthralgias and cryoglobulinemia during protease inhibitor therapy in a patient infected with human immunodeficiency virus and hepatitis C virus.
Asthma
The impact of HIV on the prevalence of asthma in Uganda: a general population survey.
Atherosclerosis
Acipimox, an Inhibitor of Lipolysis, Attenuates Atherogenesis in LDLR-Null Mice Treated With HIV Protease Inhibitor Ritonavir.
Atherosclerosis
Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice.
Atherosclerosis
Capsaicin blocks HIV protease inhibitor ritonavir-induced vascular dysfunction in porcine pulmonary arteries.
Atherosclerosis
Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors.
Atherosclerosis
Estrogen receptor-alpha mediates gender differences in atherosclerosis induced by HIV protease inhibitors.
Atherosclerosis
HIV protease inhibitor lopinavir-induced TNF-alpha and IL-6 expression is coupled to the unfolded protein response and ERK signaling pathways in macrophages.
Atherosclerosis
HIV protease inhibitors activate the unfolded protein response in macrophages: implication for atherosclerosis and cardiovascular disease.
Atherosclerosis
HIV protease inhibitors-induced atherosclerosis: prevention by alpha-tocopherol.
Atherosclerosis
Nucleoside reverse transcriptase inhibitors prevent HIV protease inhibitor-induced atherosclerosis by ubiquitination and degradation of protein kinase C.
Babesiosis
HIV protease inhibitors block parasite signal peptide peptidases and prevent growth of Babesia microti parasites in erythrocytes.
Brain Injuries
Brain injury caused by HIV protease inhibitors: role of lipodystrophy and insulin resistance.
Brain Injuries
Designer Adiponectin Receptor Agonist Stabilizes Metabolic Function and Prevents Brain Injury Caused by HIV Protease Inhibitors.
Breast Neoplasms
Comparison of ABC transporter modulation by atazanavir in lymphocytes and human brain endothelial cells: ABC transporters are involved in the atazanavir-limited passage across an in vitro human model of the blood-brain barrier.
Breast Neoplasms
Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer.
Breast Neoplasms
Enhanced killing of chemo-resistant breast cancer cells via controlled aggravation of ER stress.
Breast Neoplasms
HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).
Breast Neoplasms
P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir.
Breast Neoplasms
Preferential killing of triple-negative breast cancer cells in vitro and in vivo when pharmacological aggravators of endoplasmic reticulum stress are combined with autophagy inhibitors.
Breast Neoplasms
Re: Selective Inhibition of Her2-Positive Breast Cancer Cells by the HIV Protease Inhibitor Nelfinavir.
Breast Neoplasms
Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir.
Bursitis
Adhesive capsulitis of shoulder and treatment with protease inhibitors in patients with human immunodeficiency virus infection: report of 8 cases.
Candidiasis
Absent reduction by HIV protease inhibitors of Candida albicans adhesion to endothelial cells.
Candidiasis
Dissimilar attenuation of Candida albicans virulence properties by human immunodeficiency virus type 1 protease inhibitors.
Candidiasis
Frequency of oropharyngeal candidiasis in HIV-infected patients on protease inhibitor therapy.
Candidiasis
HIV protease inhibitors attenuate adherence of Candida albicans to epithelial cells in vitro.
Candidiasis
HIV-Protease inhibitors reduce cell adherence of Candida albicans strains by inhibition of yeast secreted aspartic proteases.
Candidiasis
Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro.
Candidiasis
Oropharyngeal candidiasis in HIV(+) patients may influence the selection of HIV-1 protease variants.
Carcinoma
A metabolomics investigation into the effects of HIV protease inhibitors on HPV16 E6 expressing cervical carcinoma cells.
Carcinoma
Amprenavir inhibits the migration in human hepatocarcinoma cell in vitro and the growth of xenografts in vivo.
Carcinoma
HIV Protease Inhibitors Block HPV16-Induced Murine Cervical Carcinoma and Promote Vessel Normalization in Association with MMP-9 Inhibition and TIMP-3 Induction.
Carcinoma
Lopinavir shows greater specificity than zinc finger ejecting compounds as a potential treatment for human papillomavirus-related lesions.
Carcinoma
Lopinavir up-regulates expression of the antiviral protein ribonuclease L in human papillomavirus-positive cervical carcinoma cells.
Carcinoma
Raman chemical mapping reveals site of action of HIV protease inhibitors in HPV16 E6 expressing cervical carcinoma cells.
Carcinoma
Ritonavir or saquinavir impair the invasion of cervical intraepithelial neoplasia cells via a reduction of MMP expression and activity.
Carcinoma
Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro.
Carcinoma
The HIV protease inhibitor ritonavir synergizes with butyrate for induction of apoptotic cell death and mediates expression of heme oxygenase-1 in DLD-1 colon carcinoma cells.
Carcinoma, Hepatocellular
The HIV protease inhibitor indinavir impairs glycogen synthesis in HepG2 hepatoma cells.
Carcinoma, Hepatocellular
The HIV-1 protease inhibitor indinavir impairs insulin signalling in HepG2 hepatoma cells.
Carcinoma, Non-Small-Cell Lung
A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical response.
Carcinoma, Non-Small-Cell Lung
Clinical Outcomes of the HIV Protease Inhibitor Nelfinavir With Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-Small Cell Lung Cancer: A Phase 1/2 Trial.
Carcinoma, Squamous Cell
HIV Protease Inhibitors Sensitize Human Head and Neck Squamous Carcinoma Cells to Radiation by Activating Endoplasmic Reticulum Stress.
Cardiomyopathies
HIV protease inhibitors that block GLUT4 precipitate acute, decompensated heart failure in a mouse model of dilated cardiomyopathy.
Cardiomyopathy, Dilated
HIV protease inhibitors that block GLUT4 precipitate acute, decompensated heart failure in a mouse model of dilated cardiomyopathy.
Cardiovascular Diseases
4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, California, USA 22-25 September 2002.
Cardiovascular Diseases
Association Between Atazanavir-Induced Hyperbilirubinemia and Cardiovascular Disease in Patients Infected with HIV.
Cardiovascular Diseases
Effects of HIV protease inhibitor ritonavir on vasomotor function and endothelial nitric oxide synthase expression.
Cardiovascular Diseases
Endothelial function in HIV-infected patients receiving protease inhibitor therapy: does immune competence affect cardiovascular risk?
Cardiovascular Diseases
HIV protease inhibitor ritonavir decreases endothelium-dependent vasorelaxation and increases superoxide in porcine arteries.
Cardiovascular Diseases
HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells.
Cardiovascular Diseases
HIV protease inhibitors activate the unfolded protein response in macrophages: implication for atherosclerosis and cardiovascular disease.
Cardiovascular Diseases
HIV protease inhibitors and insulin resistance: lessons from in-vitro, rodent and healthy human volunteer models.
Cardiovascular Diseases
HIV protease inhibitors and onset of cardiovascular diseases: a central role for oxidative stress and dysregulation of the ubiquitin-proteasome system.
Cardiovascular Diseases
HIV protease inhibitors increase TNF-alpha and IL-6 expression in macrophages: involvement of the RNA-binding protein HuR.
Cardiovascular Diseases
How HIV protease inhibitors promote atherosclerotic lesion formation.
Cardiovascular Diseases
Human Immunodeficiency Virus Protease Inhibitor Ritonavir Inhibits Cholesterol Efflux from Human Macrophage-Derived Foam Cells.
Cardiovascular Diseases
Human immunodeficiency virus protease inhibitor ritonavir inhibits cholesterol efflux from human macrophage-derived foam cells.
Cardiovascular Diseases
Inhibition of P-glycoprotein by HIV protease inhibitors increases intracellular accumulation of berberine in murine and human macrophages.
Cardiovascular Diseases
Nordihydroguaiaretic acid (NDGA) inhibits ritonavir-induced endothelial dysfunction in porcine pulmonary arteries.
Carpal Tunnel Syndrome
Carpal tunnel syndrome in HIV-infected patients treated with highly active antiretroviral therapy: other case reports.
Cataract
Cysteine protease activated by expression of HIV-1 protease in transgenic mice. MIP26 (aquaporin-0) cleavage and cataract formation in vivo and ex vivo.
Cataract
Lens hydration in transgenic mice containing HIV-1 protease linked to the lens alpha A-crystallin promoter.
Cataract
Light scattering and morphology of cataract formation in transgenic mice containing the HIV-1 protease linked to the lens alpha A-crystallin promoter.
Cerebral Small Vessel Diseases
HIV protease inhibitor exposure predicts cerebral small vessel disease.
Cervical Intraepithelial Neoplasia
HIV protease inhibitors to prevent progression of cervical intraepithelial neoplasia to cervical cancer: therapeutic opportunities and challenges.
Cervical Intraepithelial Neoplasia
Ritonavir or saquinavir impair the invasion of cervical intraepithelial neoplasia cells via a reduction of MMP expression and activity.
Chemical and Drug Induced Liver Injury
Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors.
Cholangitis
Combination antiretroviral studies for patients with primary biliary cirrhosis.
Cholangitis
Role of novel retroviruses in chronic liver disease: assessing the link of human betaretrovirus with primary biliary cirrhosis.
Coinfection
Intracellular Survival of Leishmania Species That Cause Visceral Leishmaniasis Is Significantly Reduced by HIV-1 Protease Inhibitors.
Coinfection
Liver fibrosis in HIV/hepatitis C coinfection: HIV protease inhibitors may be protective.
Coma
Dosing Recommendations for Quetiapine When Coadministered With HIV Protease Inhibitors.
Communicable Diseases
The role of mutations at codons 32, 47, 54, and 90 in HIV-1 protease flap dynamics.
Congenital Abnormalities
Excisional lipectomy for HIV-associated cervicodorsal lipodystrophy.
Coronary Artery Disease
Left main coronary artery disease in a 40-year-old man receiving HIV protease inhibitors.
Coronary Artery Disease
Stent implantation for acute left main coronary artery occlusion in an HIV-infected patient on protease inhibitors.
Coronary Disease
Resveratrol Co-Treatment Attenuates the Effects of HIV Protease Inhibitors on Rat Body Weight and Enhances Cardiac Mitochondrial Respiration.
COVID-19
Combined docking methods and molecular dynamics to identify effective antiviral 2, 5-diaminobenzophenonederivatives against SARS-CoV-2.
COVID-19
Putative Inhibitors of SARS-CoV-2 Main Protease from A Library of Marine Natural Products: A Virtual Screening and Molecular Modeling Study.
COVID-19
Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for the treatment of SARS-CoV-2 infection and COVID-19.
COVID-19
SARS-CoV-2 and HIV protease inhibitors: why lopinavir/ritonavir will not work for COVID-19 infection.
COVID-19
The protease inhibitor lopinavir, boosted with ritonavir, as treatment for COVID-19: a rapid review.
Cryoglobulinemia
Arthralgias and cryoglobulinemia during protease inhibitor therapy in a patient infected with human immunodeficiency virus and hepatitis C virus.
Cryptosporidiosis
Indinavir reduces Cryptosporidium parvum infection in both in vitro and in vivo models.
Cryptosporidiosis
Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy.
Cushing Syndrome
Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy.
Cushing Syndrome
Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers.
Cushing Syndrome
[Exogenous Cushing's syndrome as a serious side-effect of therapy with ritonavir an inhaled fluticasone].
Cystic Fibrosis
Diversified Synthetic Pathway of 1, 4-Dihydropyridines: A Class of Pharmacologically Important Molecules.
Cytomegalovirus Retinitis
Increasing survival in AIDS patients with cytomegalovirus retinitis treated with combination antiretroviral therapy including HIV protease inhibitors.
Cytomegalovirus Retinitis
Regression of cytomegalovirus retinitis associated with protease-inhibitor treatment in patients with AIDS.
Dementia
Exploitation of HIV protease inhibitor Indinavir as a memory restorative agent in experimental dementia.
Dementia
HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833.
Dementia
Involvement of P-glycoprotein in the transport of saquinavir and indinavir in rat brain microvessel endothelial and microglia cell lines.
Diabetes Mellitus
Combining metformin and nelfinavir exhibits synergistic effects against the growth of human cervical cancer cells and xenograft in nude mice.
Diabetes Mellitus
Disorders of glucose metabolism in patients infected with human immunodeficiency virus.
Diabetes Mellitus
HIV protease inhibitors and insulin resistance: lessons from in-vitro, rodent and healthy human volunteer models.
Diabetes Mellitus
Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis.
Diabetes Mellitus
The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults.
Diabetes Mellitus, Type 2
Combining metformin and nelfinavir exhibits synergistic effects against the growth of human cervical cancer cells and xenograft in nude mice.
Diabetes Mellitus, Type 2
Disorders of glucose metabolism in patients infected with human immunodeficiency virus.
Diabetes Mellitus, Type 2
Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis.
Diabetes Mellitus, Type 2
The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults.
Diabetes Mellitus, Type 2
Type 2 diabetes in association with HIV-1 protease inhibitors in HIV-infected patients.
Diabetes, Gestational
Mechanisms of reduced maternal and fetal lopinavir exposure in a rat model of gestational diabetes.
Diabetic Ketoacidosis
Diabetic ketoacidosis in an HIV patient: a new mechanism of HIV protease inhibitor-induced glucose intolerance.
Drug-Related Side Effects and Adverse Reactions
Improving HIV infection management using antiretroviral plasma drug levels monitoring: a clinician's point of view.
Drug-Related Side Effects and Adverse Reactions
Stevens-Johnson syndrome caused by indinavir.
Dyslipidemias
Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice.
Dyslipidemias
Antiretroviral-therapy-associated lipoatrophy: current status and future directions.
Dyslipidemias
Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials.
Dyslipidemias
Berberine inhibits HIV protease inhibitor-induced inflammatory response by modulating ER stress signaling pathways in murine macrophages.
Dyslipidemias
Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors.
Dyslipidemias
Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy.
Dyslipidemias
Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors.
Dyslipidemias
HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages.
Dyslipidemias
Leptin replacement therapy but not dietary polyunsaturated fatty acid alleviates HIV protease inhibitor-induced dyslipidemia and lipodystrophy in mice.
Dyslipidemias
Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108.
Dyslipidemias
Pregnane X Receptor Mediates Dyslipidemia Induced by the HIV Protease Inhibitor Amprenavir in Mice.
Dyslipidemias
Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis.
Dyslipidemias
Steady-State Pharmacokinetic Interactions of Darunavir/Ritonavir With Lipid-Lowering Agent Rosuvastatin.
Dyslipidemias
The bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in mice.
Dystonia
The HIV protease inhibitor, ritonavir, corrects diverse brain phenotypes across development in mouse model of DYT-TOR1A dystonia.
Epistaxis
Efficacy of local budesonide therapy in the management of persistent hyposmia in COVID-19 patients without signs of severity: A structured summary of a study protocol for a randomised controlled trial.
Familial Primary Pulmonary Hypertension
HIV protease inhibitors in pulmonary hypertension: rationale and design of a pilot trial in idiopathic pulmonary arterial hypertension.
Fetal Growth Retardation
HIV Protease Inhibitor Use During Pregnancy Is Associated With Decreased Progesterone Levels, Suggesting a Potential Mechanism Contributing to Fetal Growth Restriction.
Foot-and-Mouth Disease
Eukaryotic initiation factor 4GI is a poor substrate for HIV-1 proteinase.
Foot-and-Mouth Disease
NS2B/3 proteolysis at the C-prM junction of the tick-borne encephalitis virus polyprotein is highly membrane dependent.
Glioblastoma
Cleavage of recombinant and cell derived human immunodeficiency virus 1 (HIV-1) Nef protein by HIV-1 protease.
Glioblastoma
HIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cells.
Glioblastoma
In vivo imaging of HIV protease activity in amplicon vector-transduced gliomas.
Glioblastoma
Inhibitory activity of human immunodeficiency virus aspartyl protease inhibitors against Encephalitozoon intestinalis evaluated by cell culture-quantitative PCR assay.
Glioma
HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress.
Glucose Intolerance
Diabetic ketoacidosis in an HIV patient: a new mechanism of HIV protease inhibitor-induced glucose intolerance.
Glucose Intolerance
HIV protease inhibitors acutely impair glucose-stimulated insulin release.
Glucose Intolerance
Stent implantation for acute left main coronary artery occlusion in an HIV-infected patient on protease inhibitors.
Glucose Intolerance
The HIV protease inhibitor indinavir decreases insulin- and contraction-stimulated glucose transport in skeletal muscle.
Heart Failure
HIV protease inhibitors that block GLUT4 precipitate acute, decompensated heart failure in a mouse model of dilated cardiomyopathy.
Hematologic Neoplasms
The NO-modified HIV protease inhibitor as a valuable drug for hematological malignancies: Role of p70S6K.
Hemophilia A
Bleeding episodes in HIV-positive patients taking HIV protease inhibitors: a case series.
Hemophilia A
Increased bleeding in HIV-positive haemophiliacs treated with antiretroviral protease inhibitors.
Hemophilia A
Severe bleeding complications in HIV-positive haemophiliac patients treated with protease inhibitors.
Hemophilia A
Significant effects of tipranavir on platelet aggregation and thromboxane B2 formation in vitro and in vivo.
Hepatitis
Characterization of real-time microarrays for simultaneous detection of HIV-1, HIV-2, and hepatitis viruses.
Hepatitis
Effects of HAART on hepatitis C, hepatitis G, and TT virus in multiply coinfected HIV-positive patients with haemophilia.
Hepatitis
Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease?
Hepatitis
Inhibition of cytochrome P450 3A: relevant drug interactions in gastroenterology.
Hepatitis B
Progress in basic and clinical research on HIV resistance: report on the XVIII International HIV Drug Resistance Workshop.
Hepatitis C
Atorvastatin and Aspirin as Adjuvant Therapy in Patients with SARS-CoV-2 Infection: A structured summary of a study protocol for a randomised controlled trial.
Hepatitis C
Development of Anti-Viral Agents Using Molecular Modeling and Virtual Screening Techniques.
Hepatitis C
Development of anti-viral agents using molecular modeling and virtual screening techniques.
Hepatitis C
Effects of HAART on hepatitis C, hepatitis G, and TT virus in multiply coinfected HIV-positive patients with haemophilia.
Hepatitis C
Effects of omeprazole and ritonavir on absorption and elimination of the hepatitis C virus NS5A inhibitor GSK2336805 in healthy adults.
Hepatitis C
Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors.
Hepatitis C
Hepatitis C virus and human immunodeficiency virus: clinical issues in coinfection.
Hepatitis C
Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease?
Hepatitis C
Mutation rate in hepatitis C virus NS3 protease is not influenced by HIV-1 protease inhibitor therapy.
Hepatitis C
Pharmacokinetic Enhancement in HIV Antiretroviral Therapy: A Comparison of Ritonavir and Cobicistat.
Hepatitis C
Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir.
Hepatitis C
Progress in basic and clinical research on HIV resistance: report on the XVIII International HIV Drug Resistance Workshop.
Hepatitis C
Searching for discrimination rules in protease proteolytic cleavage activity using genetic programming with a min-max scoring function.
Hepatitis C
Simultaneous assay for protease activities of hepatitis C virus and human immunodeficiency virus based on fluorescence detection.
Hepatitis C
Study Design Characteristics and Pharmacological Mechanisms in International Clinical Trials Registry Platform: Registered Clinical Trials on Antiviral Drugs for COVID-19.
Hepatitis C
Trends in Utilization of Statin Therapy and Contraindicated Statin Use in HIV--Infected Adults Treated With Antiretroviral Therapy From 2007 Through 2015.
Herpes Genitalis
Successful sofosbuvir lead-in monotherapy for the treatment of hepatitis C virus (HCV) infection in a pregnant woman living with HIV.
Herpes Simplex
Expression of the human immunodeficiency virus gag gene products by a replication-incompetent herpes simplex virus vector.
Herpes Simplex
Successful sofosbuvir lead-in monotherapy for the treatment of hepatitis C virus (HCV) infection in a pregnant woman living with HIV.
HIV Infections
A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor.
HIV Infections
A phase I trial of the pharmacokinetics, toxicity, and activity of KNI-272, an inhibitor of HIV-1 protease, in patients with AIDS or symptomatic HIV infection.
HIV Infections
A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution.
HIV Infections
Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis.
HIV Infections
Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers.
HIV Infections
Boosting of HIV protease inhibitors by ritonavir in the intestine: the relative role of cytochrome P450 and P-glycoprotein inhibition based on Caco-2 monolayers versus in situ intestinal perfusion in mice.
HIV Infections
Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
HIV Infections
Conformational landscape of non-B variants of HIV-1 protease: A pulsed EPR study.
HIV Infections
Crystal Structures of Highly Constrained Substrate and Hydrolysis Products Bound to HIV-1 Protease. Implications for the Catalytic Mechanism.
HIV Infections
Design of HIV Coreceptor Derived Peptides That Inhibit Viral Entry at Submicromolar Concentrations.
HIV Infections
Determination of nelfinavir free drug concentrations in plasma by equilibrium dialysis and liquid chromatography/tandem mass spectrometry: important factors for method optimization.
HIV Infections
Development of a Novel Self-Microemulsifying Drug Delivery System for Reducing HIV Protease Inhibitor-Induced Intestinal Epithelial Barrier Dysfunction.
HIV Infections
Drug resistance conferred by mutations outside the active site through alterations in the dynamic and structural ensemble of HIV-1 protease.
HIV Infections
Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits.
HIV Infections
Effect of alpha1-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro.
HIV Infections
Effect of nelfinavir on insulin metabolism, proteasome activity and protein degradation in HepG2 cells.
HIV Infections
Effect of streptozotocin-induced diabetes mellitus on the pharmacokinetics of nelfinavir in rats.
HIV Infections
Elevated adiponectin prevents HIV protease inhibitor toxicity and preserves cerebrovascular homeostasis in mice.
HIV Infections
Emtricitabine: new preparation. An antiretroviral very similar to lamivudine.
HIV Infections
Exploring the drug resistance mechanism of active site, non-active site mutations and their cooperative effects in CRF01_AE HIV-1 protease: Molecular dynamics simulations and free energy calculations.
HIV Infections
HIV Protease Cleavage of Procaspase 8 is Necessary for Death of HIV-Infected Cells.
HIV Infections
HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells.
HIV Infections
HIV protease inhibitors differentially inhibit adhesion of Candida albicans to acrylic surfaces.
HIV Infections
HIV Protease Inhibitors Disrupt Lipid Metabolism by Activating Endoplasmic Reticulum Stress and Inhibiting Autophagy Activity in Adipocytes.
HIV Infections
HIV protease inhibitors elicit volume-sensitive Cl- current in cardiac myocytes via mitochondrial ROS.
HIV Infections
HIV protease inhibitors: effects on viral maturation and physiologic function in macrophages.
HIV Infections
Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells.
HIV Infections
Impacts of drug resistance mutations on the structural asymmetry of the HIV-2 protease.
HIV Infections
In vitro activity of inhibitors of late stages of the replication of HIV in chronically infected macrophages.
HIV Infections
Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study.
HIV Infections
Interchain hydrophobic clustering promotes rigidity in HIV-1 protease flap dynamics: new insights from Molecular Dynamics.
HIV Infections
Investigating the contribution of CYP2J2 to ritonavir metabolism in vitro and in vivo.
HIV Infections
Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein.
HIV Infections
Management of HIV-infected pregnant patients in malaria-endemic areas: therapeutic and safety considerations in concomitant use of antiretroviral and antimalarial agents.
HIV Infections
Matrix metalloproteinase dysregulation in HIV infection: implications for therapeutic strategies.
HIV Infections
Nelfinavir induces liposarcoma apoptosis and cell cycle arrest by upregulating sterol regulatory element binding protein-1.
HIV Infections
Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy.
HIV Infections
No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial.
HIV Infections
Nordihydroguaiaretic acid (NDGA) inhibits ritonavir-induced endothelial dysfunction in porcine pulmonary arteries.
HIV Infections
Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction.
HIV Infections
Prescribing of contraindicated protease inhibitor and statin combinations among HIV-infected persons.
HIV Infections
Prevention of HIV protease inhibitor-induced dysregulation of hepatic lipid metabolism by raltegravir via endoplasmic reticulum stress signaling pathways.
HIV Infections
Protease inhibitors stimulate hematopoiesis and decrease apoptosis and ICE expression in CD34(+) cells.
HIV Infections
Reduction of the HIV Protease Inhibitor-Induced ER Stress and Inflammatory Response by Raltegravir in Macrophages.
HIV Infections
Risk-benefit of HMG-CoA reductase inhibitors in the treatment of HIV protease inhibitor-related hyperlipidaemia.
HIV Infections
Ritonavir and saquinavir combination therapy for the treatment of HIV infection.
HIV Infections
Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection.
HIV Infections
Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction.
HIV Infections
Structural insights into the South African HIV-1 subtype C protease: impact of hinge region dynamics and flap flexibility in drug resistance.
HIV Infections
Structure-based design of novel HIV protease inhibitors: carboxamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent nonpeptidic inhibitors.
HIV Infections
Structure-based design of novel HIV protease inhibitors: sulfonamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitors.
HIV Infections
The absorption, distribution, metabolism and elimination of bevirimat in rats.
HIV Infections
The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes.
HIV Infections
The role of combinations of HIV protease inhibitors in the management of persons with HIV infection.
HIV Infections
Timing the emergence of resistance to anti-HIV drugs with large genetic barriers.
HIV Infections
TSAO compounds: the comprehensive story of a unique family of HIV-1 specific inhibitors of reverse transcriptase.
HIV Infections
Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations.
HIV Infections
[HIV protease inhibitors (new possibilities in the treatment of HIV infection and AIDS)]
HIV Infections
[Value of saquinavir in antiretroviral treatment of adult HIV-1 infection in 2001]
Hypercholesterolemia
Gender-specific effects of HIV protease inhibitors on body mass in mice.
Hypercholesterolemia
Prevalence of elevated cholesterol and associated risk factors among perinatally HIV-infected children (4-19 years old) in Pediatric AIDS Clinical Trials Group 219C.
Hypercholesterolemia
Stent implantation for acute left main coronary artery occlusion in an HIV-infected patient on protease inhibitors.
Hyperglycemia
Antiretroviral treatment for HIV infection/AIDS and the risk of developing hyperglycemia and hyperlipidemia.
Hyperglycemia
Pharmacokinetic and metabolic effects of American ginseng (Panax quinquefolius) in healthy volunteers receiving the HIV protease inhibitor indinavir.
Hyperglycemia
Rapid progression of atherosclerotic coronary artery disease in patients with human immunodeficiency virus infection.
Hyperglycemia
Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction.
Hyperlipidemias
Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice.
Hyperlipidemias
Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy.
Hyperlipidemias
Antiretroviral treatment for HIV infection/AIDS and the risk of developing hyperglycemia and hyperlipidemia.
Hyperlipidemias
Brain injury caused by HIV protease inhibitors: role of lipodystrophy and insulin resistance.
Hyperlipidemias
HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia.
Hyperlipidemias
Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment.
Hyperlipidemias
Identification of proteasome gene regulation in a rat model for HIV protease inhibitor-induced hyperlipidemia.
Hyperlipidemias
Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study.
Hyperlipidemias
Indinavir alters sterol and fatty acid homeostatic mechanisms in primary rat hepatocytes by increasing levels of activated sterol regulatory element-binding proteins and decreasing cholesterol 7alpha-hydroxylase mRNA levels.
Hyperlipidemias
Indinavir induces acute and reversible peripheral insulin resistance in rats.
Hyperlipidemias
Investigating the cellular targets of HIV protease inhibitors: implications for metabolic disorders and improvements in drug therapy.
Hyperlipidemias
Pharmacokinetics of human immunodeficiency virus protease inhibitor, nelfinavir, in poloxamer 407-induced hyperlipidemic model rats.
Hyperlipidemias
Pravastatin in hyperlipidemia secondary to HIV protease inhibitors without response to fenofibrate: a brief preliminary report.
Hyperlipidemias
Prescribing of contraindicated protease inhibitor and statin combinations among HIV-infected persons.
Hyperlipidemias
Prevention of HIV protease inhibitor-induced dysregulation of hepatic lipid metabolism by raltegravir via endoplasmic reticulum stress signaling pathways.
Hyperlipidemias
Rapid progression of atherosclerotic coronary artery disease in patients with human immunodeficiency virus infection.
Hyperlipidemias
Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction.
Hypersensitivity
A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir.
Hypersensitivity
Continued therapy with HIV-1 protease inhibitors, despite previous hypersensitivity reactions, through coadministration of prednisone.
Hypersensitivity
Efficacy of local budesonide therapy in the management of persistent hyposmia in COVID-19 patients without signs of severity: A structured summary of a study protocol for a randomised controlled trial.
Hypersensitivity
Prevalence of the HIV protease mutation N88S causing hypersensitivity to amprenavir.
Hypertension
Capsaicin blocks HIV protease inhibitor ritonavir-induced vascular dysfunction in porcine pulmonary arteries.
Hypertension
Dual inhibitors for aspartic proteases HIV-1 PR and renin: advancements in AIDS-hypertension-diabetes linkage via molecular dynamics, inhibition assays, and binding free energy calculations.
Hypertension
HIV protease inhibitors in pulmonary hypertension: rationale and design of a pilot trial in idiopathic pulmonary arterial hypertension.
Hypertension
Nordihydroguaiaretic acid (NDGA) inhibits ritonavir-induced endothelial dysfunction in porcine pulmonary arteries.
Hypertension
Rapid progression of atherosclerotic coronary artery disease in patients with human immunodeficiency virus infection.
Hypertension, Pulmonary
Effects of HIV Protease Inhibitors on Progression of Monocrotaline- and Hypoxia-Induced Pulmonary Hypertension in Rats.
Hypertension, Pulmonary
HIV protease inhibitors in pulmonary hypertension: rationale and design of a pilot trial in idiopathic pulmonary arterial hypertension.
Hypertriglyceridemia
Ritonavir impairs lipoprotein lipase-mediated lipolysis and decreases uptake of fatty acids in adipose tissue.
Hypertriglyceridemia
Stent implantation for acute left main coronary artery occlusion in an HIV-infected patient on protease inhibitors.
Hypotension
Inhibition of cytochrome P450 3A: relevant drug interactions in gastroenterology.
Infections
A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection.
Infections
Amino Functionalized Novel Cholic Acid Derivatives Induce HIV-1 Replication and Syncytia Formation in T Cells.
Infections
Analysis of HIV-1 protease gene reveals frequent multiple infections followed by recombination among drug treated individuals living in São Paulo and Santos, Brazil.
Infections
Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors.
Infections
Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection: evidence for a role of protease in the early phase.
Infections
Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease.
Infections
Bioequivalence study of two oral tablet formulations containing saquinavir mesylate boosted with ritonavir in healthy male subjects.
Infections
Captopril and renal survival in patients with human immunodeficiency virus nephropathy.
Infections
Comparative description of haplotype structure and genetic diversity of MDR1 (ABCB1) in HIV-positive and HIV-negative populations.
Infections
Conditional human immunodeficiency virus type 1 protease mutants show no role for the viral protease early in virus replication.
Infections
Correlation between changes in plasma HIV RNA levels and in plasma infectivity in response to antiretroviral therapy.
Infections
Coupling of an Acyl Migration Prodrug Strategy with Bio-activation To Improve Oral Delivery of the HIV-1 Protease Inhibitor Atazanavir.
Infections
Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease.
Infections
Development of HIV-1 protease expression methods using the T7 phage promoter system.
Infections
Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase.
Infections
Effect of HIV aspartyl protease inhibitors on experimental infection with a cystogenic Me49 strain of Toxoplasma gondii.
Infections
Effects of tipranavir, darunavir, and ritonavir on platelet function, coagulation, and fibrinolysis in healthy volunteers.
Infections
Efficient Identification of Human Immunodeficiency Virus Type 1 Mutants Resistant to a Protease Inhibitor Using a Random Mutant Library.
Infections
Ellagic acid & gallic acid from Lagerstroemia speciosa L. inhibit HIV-1 infection through inhibition of HIV-1 protease & reverse transcriptase activity.
Infections
Functional characterization of the protease of human endogenous retrovirus, K10: can it complement HIV-1 protease?
Infections
GCN2 has inhibitory effect on human immunodeficiency virus-1 protein synthesis and is cleaved upon viral infection.
Infections
Hepatitis C virus and human immunodeficiency virus: clinical issues in coinfection.
Infections
HIV protease inhibitors attenuate adherence of Candida albicans to epithelial cells in vitro.
Infections
HIV protease inhibitors block parasite signal peptide peptidases and prevent growth of Babesia microti parasites in erythrocytes.
Infections
HIV-1 protease does not play a critical role in the early stages of HIV-1 infection.
Infections
Human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns among treatment-naive patients in different stages of infection in Rio de Janeiro, Brazil.
Infections
Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention.
Infections
Investigation of novel indole-based HIV-1 protease inhibitors using virtual screening and text mining.
Infections
Molecular insights of protein contour recognition with ligand pharmacophoric sites through combinatorial library design and MD simulation in validating HTLV-1 PR inhibitors.
Infections
Peptide inhibitors of HIV-1 protease and viral infection of peripheral blood lymphocytes based on HIV-1 Vif.
Infections
Pharmacokinetics of Rifabutin in Japanese HIV-Infected Patients with or without Antiretroviral Therapy.
Infections
Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes.
Infections
Preclinical evaluation of antiviral activity and toxicity of Abbott A77003, an inhibitor of the human immunodeficiency virus type 1 protease.
Infections
Processing of the precursor of NF-kappa B by the HIV-1 protease during acute infection.
Infections
Purification and biochemical characterization of recombinant simian immunodeficiency virus protease and comparison to human immunodeficiency virus type 1 protease.
Infections
Rapid quantification of HIV protease inhibitors in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Infections
Resveratrol protects against protease inhibitor-induced reactive oxygen species production, reticulum stress and lipid raft perturbation.
Infections
Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy.
Infections
SARS-CoV-2 and HIV protease inhibitors: why lopinavir/ritonavir will not work for COVID-19 infection.
Infections
Sequence analysis of the HIV-1 protease coding region of 18 HIV-1-infected patients prior to HAART and possible implications on HAART.
Infections
Severe bleeding complications in HIV-positive haemophiliac patients treated with protease inhibitors.
Infections
Structure-activity relationships of HIV-1 PR inhibitors containing AHPBA--II. Modification of pyrrolidine ring at P1' proline.
Infections
Synergistic drug interactions of an HIV-1 protease inhibitor with AZT in different in vitro models of HIV-1 infection.
Infections
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.
Infections
The role of select subtype polymorphisms on HIV-1 protease conformational sampling and dynamics.
Infections
The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research.
Infections
Towards tricking a pathogen's protease into fighting infection: the 3D structure of a stable circularly permuted onconase variant cleavedby HIV-1 protease.
Infections
Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy.
Infections
Vector replication and expression of HIV-1 antigens by the HIV/AIDS vaccine candidate MVA-B is not affected by HIV-1 protease inhibitors.
Infections
WNT/beta-catenin signaling is involved in regulation of osteoclast differentiation by human immunodeficiency virus protease inhibitor ritonavir: relationship to human immunodeficiency virus-linked bone mineral loss.
Influenza in Birds
Expanding the frontiers of existing antiviral drugs: possible effects of HIV-1 protease inhibitors against SARS and avian influenza.
Influenza, Human
AIMECS 99--AFMC International Medicinal Chemistry Symposium. 12-15 September 1999, Beijing, China.
Influenza, Human
Development of Anti-Viral Agents Using Molecular Modeling and Virtual Screening Techniques.
Influenza, Human
Development of anti-viral agents using molecular modeling and virtual screening techniques.
Influenza, Human
In-silico profiling of the biological activities of Amaryllidaceae alkaloids.
Influenza, Human
Recent advances in the study, prevention, and treatment of infectious diseases.
Insulin Resistance
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.
Insulin Resistance
Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors.
Insulin Resistance
Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy.
Insulin Resistance
Antiretroviral-therapy-associated lipoatrophy: current status and future directions.
Insulin Resistance
Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers.
Insulin Resistance
Brain injury caused by HIV protease inhibitors: role of lipodystrophy and insulin resistance.
Insulin Resistance
Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors.
Insulin Resistance
Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection.
Insulin Resistance
Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal.
Insulin Resistance
Effect of nelfinavir on insulin metabolism, proteasome activity and protein degradation in HepG2 cells.
Insulin Resistance
Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically.
Insulin Resistance
Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers.
Insulin Resistance
Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy.
Insulin Resistance
HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study.
Insulin Resistance
HIV protease inhibitors act as competitive inhibitors of the cytoplasmic glucose binding site of GLUTs with differing affinities for GLUT1 and GLUT4.
Insulin Resistance
HIV protease inhibitors activate the adipocyte renin angiotensin system.
Insulin Resistance
HIV protease inhibitors acutely impair glucose-stimulated insulin release.
Insulin Resistance
HIV protease inhibitors and insulin resistance: lessons from in-vitro, rodent and healthy human volunteer models.
Insulin Resistance
HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo.
Insulin Resistance
HIV protease inhibitors that block GLUT4 precipitate acute, decompensated heart failure in a mouse model of dilated cardiomyopathy.
Insulin Resistance
HIV-1 protease inhibitors induce an increase of triglyceride level in HIV-infected men without modification of insulin sensitivity: a longitudinal study.
Insulin Resistance
In vitro and in vivo prevention of HIV protease inhibitor-induced insulin resistance by a novel small molecule insulin receptor activator.
Insulin Resistance
Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study.
Insulin Resistance
Indinavir and nelfinavir inhibit proximal insulin receptor signalling and salicylate abrogates inhibition: Potential role of the NFkappa B pathway.
Insulin Resistance
Indinavir induces acute and reversible peripheral insulin resistance in rats.
Insulin Resistance
Investigating the cellular targets of HIV protease inhibitors: implications for metabolic disorders and improvements in drug therapy.
Insulin Resistance
Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells.
Insulin Resistance
Nelfinavir-induced insulin resistance is associated with impaired plasma membrane recruitment of the PI 3-kinase effectors Akt/PKB and PKC-zeta.
Insulin Resistance
No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial.
Insulin Resistance
Pharmacokinetic and metabolic effects of American ginseng (Panax quinquefolius) in healthy volunteers receiving the HIV protease inhibitor indinavir.
Insulin Resistance
Post-receptoral adipocyte insulin resistance induced by nelfinavir is caused by insensitivity of PKB/Akt to phosphatidylinositol-3,4,5-trisphosphate.
Insulin Resistance
Severe Impairment of Endothelial Function with the HIV-1 Protease Inhibitor Indinavir is not Mediated by Insulin Resistance in Healthy Subjects.
Insulin Resistance
The Acute Effects of HIV Protease Inhibitors on Insulin Suppression of Glucose Production in Healthy HIV-Negative Men.
Insulin Resistance
The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults.
Insulin Resistance
The HIV protease inhibitor indinavir decreases insulin- and contraction-stimulated glucose transport in skeletal muscle.
Insulin Resistance
The HIV protease inhibitor indinavir impairs glycogen synthesis in HepG2 hepatoma cells.
Insulin Resistance
The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance.
Insulin Resistance
The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes.
Insulin Resistance
The mechanism of insulin resistance caused by HIV protease inhibitor therapy.
Insulin Resistance
[Lipodystrophy and 'buffalo hump' during treatment with HIV protease inhibitors]
Insulinoma
[Effects of various HIV protease inhibitors on function of rat insulinoma cells]
Kidney Neoplasms
17-Allylamino-17-demethoxygeldanamycin and ritonavir inhibit renal cancer growth by inhibiting the expression of heat shock factor-1.
Kidney Neoplasms
Delanzomib Interacts with Ritonavir Synergistically to Cause Endoplasmic Reticulum Stress in Renal Cancer Cells.
Kidney Neoplasms
Nelfinavir Induces Endoplasmic Reticulum Stress and Sensitizes Renal Cancer Cells to TRAIL.
Kidney Neoplasms
Panobinostat and Nelfinavir Inhibit Renal Cancer Growth by Inducing Endoplasmic Reticulum Stress.
Kidney Neoplasms
Ritonavir acts synergistically with panobinostat to enhance histone acetylation and inhibit renal cancer growth.
Kidney Neoplasms
Ritonavir Interacts With Bortezomib to Enhance Protein Ubiquitination and Histone Acetylation Synergistically in Renal Cancer Cells.
Latent Infection
Specific Elimination of Latently HIV-1 Infected Cells Using HIV-1 Protease-Sensitive Toxin Nanocapsules.
Leishmaniasis
Anti-HIV drugs, lopinavir/ritonavir and atazanavir, modulate innate immune response triggered by Leishmania in macrophages: The role of NF-?B and PPAR-?.
Leishmaniasis
HIV aspartyl protease inhibitors modify the percentage of activated leukocytes, as well as serum levels of IL-17A and NO during experimental leishmaniasis.
Leishmaniasis, Visceral
HIV-1 protease inhibitors for treatment of visceral leishmaniasis in HIV-co-infected individuals.
Leishmaniasis, Visceral
Intracellular Survival of Leishmania Species That Cause Visceral Leishmaniasis Is Significantly Reduced by HIV-1 Protease Inhibitors.
Leukemia
Antiretroviral activities of protease inhibitors against murine leukemia virus and simian immunodeficiency virus in tissue culture.
Leukemia
Characterization of the murine leukemia virus protease and its comparison with the human immunodeficiency virus type 1 protease.
Leukemia
Cleavage of the murine leukemia virus transmembrane env protein by human immunodeficiency virus type 1 protease: transdominant inhibition by matrix mutations.
Leukemia
Effects of SKF 108922, an HIV-1 protease inhibitor, on retrovirus replication in mice.
Leukemia
HIV type 1 protease inhibitors fail to inhibit HTLV-I Gag processing in infected cells.
Leukemia
HIV-1 protease inhibitors decrease proliferation and induce differentiation of human myelocytic leukemia cells.
Leukemia
The HIV protease inhibitor, nelfinavir, as a novel therapeutic approach for the treatment of refractory pediatric leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Investigating and targeting chronic lymphocytic leukemia metabolism with the human immunodeficiency virus protease inhibitor ritonavir and metformin.
Leukemia, Myeloid
HIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2.
Leukemia, Myeloid
HIV-1 protease inhibitor ritonavir potentiates the effect of 1,25-dihydroxyvitamin D3 to induce growth arrest and differentiation of human myeloid leukemia cells via down-regulation of CYP24.
Leukemia, Myeloid
HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo.
Leukemia, Myeloid
HIV-1 protease inhibitors decrease proliferation and induce differentiation of human myelocytic leukemia cells.
Leukemia, Promyelocytic, Acute
HIV-1 protease inhibitors decrease proliferation and induce differentiation of human myelocytic leukemia cells.
Leukemia, T-Cell
HIV type 1 protease inhibitors fail to inhibit HTLV-I Gag processing in infected cells.
Leukemia-Lymphoma, Adult T-Cell
Design of potent aspartic protease inhibitors to treat various diseases.
Leukemia-Lymphoma, Adult T-Cell
Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir.
Lipodystrophy
A Potent HIV Protease Inhibitor, Darunavir, Does Not Inhibit ZMPSTE24 or Lead to an Accumulation of Farnesyl-prelamin A in Cells.
Lipodystrophy
A Reduction Grade of Lipodystrophy and Limited Side Effects after HAART Regimen with Raltegravir, Lamivudine, Darunavir and Ritonavir in an HIV-1 Infected Patient after Six Years of Antiretroviral Therapy.
Lipodystrophy
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.
Lipodystrophy
Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy.
Lipodystrophy
Brain injury caused by HIV protease inhibitors: role of lipodystrophy and insulin resistance.
Lipodystrophy
Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors.
Lipodystrophy
Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir is not sufficient to inhibit differentiation.
Lipodystrophy
Effect of nelfinavir on insulin metabolism, proteasome activity and protein degradation in HepG2 cells.
Lipodystrophy
Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy.
Lipodystrophy
Farnesyltransferase inhibitors prevent HIV protease inhibitor (lopinavir/ritonavir)-induced lipodystrophy and metabolic syndrome in mice.
Lipodystrophy
HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study.
Lipodystrophy
HIV protease inhibitors inhibit FACE1/ZMPSTE24: a mechanism for acquired lipodystrophy in patients on highly active antiretroviral therapy?
Lipodystrophy
HIV protease inhibitors, the lipodystrophy syndrome and polycystic ovary syndrome--is there a link?
Lipodystrophy
HIV-1 protease inhibitor-associated partial lipodystrophy: clinicopathologic review of 14 cases.
Lipodystrophy
Human lipodystrophies linked to mutations in A-type lamins and to HIV protease inhibitor therapy are both associated with prelamin A accumulation, oxidative stress and premature cellular senescence.
Lipodystrophy
Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy.
Lipodystrophy
In vitro evidence of inhibition of mitochondrial protease processing by HIV-1 protease inhibitors in yeast: a possible contribution to lipodystrophy syndrome.
Lipodystrophy
Indinavir induces acute and reversible peripheral insulin resistance in rats.
Lipodystrophy
Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytes.
Lipodystrophy
Leptin replacement therapy but not dietary polyunsaturated fatty acid alleviates HIV protease inhibitor-induced dyslipidemia and lipodystrophy in mice.
Lipodystrophy
LMNA mutations resulting in lipodystrophy and HIV protease inhibitors trigger vascular smooth muscle cell senescence and calcification: Role of ZMPSTE24 downregulation.
Lipodystrophy
Local treatment of facial lipodystrophy in patients receiving HIV protease inhibitor therapy.
Lipodystrophy
Nelfinavir induces adipocyte insulin resistance through the induction of oxidative stress: differential protective effect of antioxidant agents.
Lipodystrophy
Nelfinavir induces liposarcoma apoptosis and cell cycle arrest by upregulating sterol regulatory element binding protein-1.
Lipodystrophy
Nelfinavir-induced insulin resistance is associated with impaired plasma membrane recruitment of the PI 3-kinase effectors Akt/PKB and PKC-zeta.
Lipodystrophy
No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial.
Lipodystrophy
Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study.
Lipodystrophy
Ritonavir impairs lipoprotein lipase-mediated lipolysis and decreases uptake of fatty acids in adipose tissue.
Lipodystrophy
Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis.
Lipodystrophy
Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation.
Lipodystrophy
Sp1 transcription factor interaction with accumulated prelamin a impairs adipose lineage differentiation in human mesenchymal stem cells: essential role of sp1 in the integrity of lipid vesicles.
Lipodystrophy
Stent implantation for acute left main coronary artery occlusion in an HIV-infected patient on protease inhibitors.
Lipodystrophy
Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy.
Lipodystrophy
Synergistic antiadipogenic effects of HIV type 1 protease inhibitors with tumor necrosis factor alpha: suppression of extracellular insulin action mediated by extracellular matrix-degrading proteases.
Lipodystrophy
[Lipodystrophy and 'buffalo hump' during treatment with HIV protease inhibitors]
Lipoma
Multiple circumscribed subcutaneous lipomas associated with use of human immunodeficiency virus protease inhibitors?
Liposarcoma
Nelfinavir induces liposarcoma apoptosis and cell cycle arrest by upregulating sterol regulatory element binding protein-1.
Liver Cirrhosis
Liver fibrosis in HIV/hepatitis C coinfection: HIV protease inhibitors may be protective.
Liver Cirrhosis, Biliary
Role of novel retroviruses in chronic liver disease: assessing the link of human betaretrovirus with primary biliary cirrhosis.
Lung Neoplasms
A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical response.
Lung Neoplasms
Clinical Outcomes of the HIV Protease Inhibitor Nelfinavir With Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-Small Cell Lung Cancer: A Phase 1/2 Trial.
Lung Neoplasms
NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines.
Lung Neoplasms
The Human Immunodeficiency Virus Protease Inhibitor Ritonavir Inhibits Lung Cancer Cells, in Part, by Inhibition of Survivin.
Lymphocytic Choriomeningitis
An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses.
Lymphoma
Combined radiation sensitizing and anti-angiogenic effects of ionizing radiation and the protease inhibitor ritonavir in a head and neck carcinoma model.
Lymphoma
HIV protease inhibitor Lopinavir induces apoptosis of primary effusion lymphoma cells via suppression of NF-?B pathway.
Lymphoma, Primary Effusion
HIV protease inhibitor Lopinavir induces apoptosis of primary effusion lymphoma cells via suppression of NF-?B pathway.
Malaria
Altered Plasmodium falciparum Sensitivity to the Antiretroviral Protease Inhibitor Lopinavir Associated with Polymorphisms in pfmdr1.
Malaria
Combined docking methods and molecular dynamics to identify effective antiviral 2, 5-diaminobenzophenonederivatives against SARS-CoV-2.
Malaria
Distinct effects of HIV protease inhibitors and ERAD inhibitors on zygote to ookinete transition of the malaria parasite.
Malaria
Does a significant reduction in malaria risk make lopinavir/ritonavir-based ART cost-effective for children with HIV in co-endemic, low-resource settings?
Malaria
HIV protease inhibitors, indinavir or nelfinavir, augment antimalarial action of artemisinin in vitro.
Malaria
HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study.
Malaria
In vitro interactions between antiretroviral protease inhibitors and artemisinin endoperoxides against Plasmodium falciparum.
Malaria
Malaria in HIV-Infected Children Receiving HIV Protease-Inhibitor- Compared with Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy, IMPAACT P1068s, Substudy to P1060.
Malaria
Neither the HIV protease inhibitor lopinavir-ritonavir nor the antimicrobial trimethoprim-sulfamethoxazole prevent malaria relapse in plasmodium cynomolgi-infected non-human primates.
Malaria
Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria.
Malaria
Presence of Plasmodium falciparum DNA in Plasma Does Not Predict Clinical Malaria in an HIV-1 Infected Population.
Malaria
Ritonavir-boosted indinavir but not lopinavir inhibits erythrocytic stage Plasmodium knowlesi malaria in rhesus macaques.
Malaria
Synergy of human immunodeficiency virus protease inhibitors with chloroquine against Plasmodium falciparum in vitro and Plasmodium chabaudi in vivo.
Melanoma
HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest.
Melanoma
Lopinavir-NO, a nitric oxide-releasing HIV protease inhibitor, suppresses the growth of melanoma cells in vitro and in vivo.
Memory Disorders
Exploitation of HIV protease inhibitor Indinavir as a memory restorative agent in experimental dementia.
Metabolic Syndrome
A Potent HIV Protease Inhibitor, Darunavir, Does Not Inhibit ZMPSTE24 or Lead to an Accumulation of Farnesyl-prelamin A in Cells.
Metabolic Syndrome
Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy?
Metabolic Syndrome
Farnesyltransferase inhibitors prevent HIV protease inhibitor (lopinavir/ritonavir)-induced lipodystrophy and metabolic syndrome in mice.
Metabolic Syndrome
HIV protease inhibitors activate the adipocyte renin angiotensin system.
Metabolic Syndrome
HIV protease inhibitors increase TNF-alpha and IL-6 expression in macrophages: involvement of the RNA-binding protein HuR.
Microsporidiosis
Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy.
Multiple Myeloma
HIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2.
Multiple Myeloma
In Silico Modeling-based Identification of Glucose Transporter 4 (GLUT4)-selective Inhibitors for Cancer Therapy.
Multiple Myeloma
The HIV-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the multiple myeloma cells proliferation in vitro and in vivo.
Multiple Myeloma
Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).
Mycoses
Absent reduction by HIV protease inhibitors of Candida albicans adhesion to endothelial cells.
Mycoses
The crystal structure of protease Sapp1p from Candida parapsilosis in complex with the HIV protease inhibitor ritonavir.
Myocardial Infarction
HIV protease inhibitors activate the unfolded protein response in macrophages: implication for atherosclerosis and cardiovascular disease.
Myocardial Infarction
Increasing morbidity from myocardial infarction during HIV protease inhibitor treatment?
Myocardial Infarction
Stent implantation for acute left main coronary artery occlusion in an HIV-infected patient on protease inhibitors.
Neoplasms
A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors.
Neoplasms
An HIV protease inhibitor, ritonavir targets the nuclear factor-kappaB and inhibits the tumor growth and infiltration of EBV-positive lymphoblastoid B cells.
Neoplasms
Co-treatment With HIV Protease Inhibitor Nelfinavir Greatly Increases Late-phase Apoptosis of Drug-resistant KBV20C Cancer Cells Independently of P-Glycoprotein Inhibition.
Neoplasms
Combined radiation sensitizing and anti-angiogenic effects of ionizing radiation and the protease inhibitor ritonavir in a head and neck carcinoma model.
Neoplasms
Combining metformin and nelfinavir exhibits synergistic effects against the growth of human cervical cancer cells and xenograft in nude mice.
Neoplasms
Cytotoxic, cytostatic and HIV-1 PR inhibitory activities of the soft coral Litophyton arboreum.
Neoplasms
Effects of HIV protease, nucleoside/non-nucleoside reverse transcriptase inhibitors on Bax, Bcl-2 and apoptosis in two cervical cell lines.
Neoplasms
Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: Results of a Phase II clinical trial.
Neoplasms
Extracellular binding of indinavir to matrix metalloproteinase-2 and the alpha-7-nicotinic acetylcholine receptor: implications for use in cancer treatment.
Neoplasms
Genetic algorithm optimization in drug design QSAR: Bayesian-regularized genetic neural networks (BRGNN) and genetic algorithm-optimized support vectors machines (GA-SVM).
Neoplasms
Hemeoxygenase-1 as a novel driver in ritonavir-induced insulin resistance in HIV-1-infected patients.
Neoplasms
HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo.
Neoplasms
HIV protease inhibitors to prevent progression of cervical intraepithelial neoplasia to cervical cancer: therapeutic opportunities and challenges.
Neoplasms
HIV-1 protease inhibitors decrease proliferation and induce differentiation of human myelocytic leukemia cells.
Neoplasms
HIV-1 Protease Inhibitors Slow HPV16-Driven Cell Proliferation through Targeted Depletion of Viral E6 and E7 Oncoproteins.
Neoplasms
HIV-protease inhibitors for the treatment of cancer: Repositioning HIV protease inhibitors while developing more potent NO-hybridized derivatives?
Neoplasms
Human immunodeficiency virus protease inhibitors reduce the growth of human tumors via a proteasome-independent block of angiogenesis and matrix metalloproteinases.
Neoplasms
Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention.
Neoplasms
Isolation and synthesis of a new bioactive ellagic acid derivative from Combretum yunnanensis.
Neoplasms
MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity.
Neoplasms
Molecular and enzymatic characterization of XMRV protease by a cell-free proteolytic analysis.
Neoplasms
Moloney murine leukemia virus protease: bacterial expression and characterization of the purified enzyme.
Neoplasms
Nelfinavir and Its Active Metabolite M8 Are Partial Agonists and Competitive Antagonists of the Human Pregnane X Receptor.
Neoplasms
Nelfinavir Down-regulates Hypoxia-Inducible Factor 1{alpha} and VEGF Expression and Increases Tumor Oxygenation: Implications for Radiotherapy.
Neoplasms
Nelfinavir induces mitochondria protection by ERK1/2-mediated mcl-1 stabilization that can be overcome by sorafenib.
Neoplasms
Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo.
Neoplasms
Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy.
Neoplasms
Phase 1 trial of nelfinavir added to standard cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancer.
Neoplasms
Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer.
Neoplasms
Ritonavir or saquinavir impair the invasion of cervical intraepithelial neoplasia cells via a reduction of MMP expression and activity.
Neoplasms
Role of P-glycoprotein in the distribution of the HIV protease inhibitor atazanavir in the brain and male genital tract.
Neoplasms
Saquinavir-NO-targeted S6 protein mediates sensitivity of androgen-dependent prostate cancer cells to TRAIL.
Neoplasms
Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells.
Neoplasms
Targeting the AKT pathway: Repositioning HIV protease inhibitors as radiosensitizers.
Neoplasms
The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt.
Neoplasms
The HIV protease and PI3K/Akt inhibitor nelfinavir does not improve the curative effect of fractionated irradiation in PC-3 prostate cancer in vitro and in vivo.
Neoplasms
The HIV protease inhibitor indinavir down-regulates the expression of the pro-angiogenic MT1-MMP by human endothelial cells.
Neoplasms
The HIV-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the multiple myeloma cells proliferation in vitro and in vivo.
Neoplasms
The human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological malignancies.
Neoplasms
The Impact of Human Papilloma Viruses, Matrix Metallo-Proteinases and HIV Protease Inhibitors on the Onset and Progression of Uterine Cervix Epithelial Tumors: A Review of Preclinical and Clinical Studies.
Nephritis, Interstitial
Papillary necrosis associated with the HIV protease inhibitor indinavir.
Nephrolithiasis
Acute renal failure due to indinavir crystalluria and nephrolithiasis: report of two cases.
Nephrotic Syndrome
Saquinavir in steroid-dependent and -resistant nephrotic syndrome: a pilot study.
Neuroblastoma
Kynostatin and 17beta-estradiol prevent the apoptotic death of human neuroblastoma cells exposed to HIV-1 protease.
Obesity
Effects of obesity induced by high-fat diet on the pharmacokinetics of nelfinavir, a HIV protease inhibitor, in laboratory rats.
Obesity
Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction.
Obesity, Abdominal
The HIV protease inhibitor indinavir decreases insulin- and contraction-stimulated glucose transport in skeletal muscle.
Opportunistic Infections
Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy.
Opportunistic Infections
Crystal structure of the retroviral protease-like domain of a protozoal DNA damage-inducible 1 protein.
Opportunistic Infections
HIV protease inhibitors influence the prevalence of oral candidosis in HIV-infected patients: a 2-year study.
Opportunistic Infections
Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed?
Osteonecrosis
Osteonecrosis of the femoral head in patients receiving HIV protease inhibitors.
Ovarian Neoplasms
Nelfinavir induces the unfolded protein response in ovarian cancer cells, resulting in ER vacuolization, cell cycle retardation and apoptosis.
Ovarian Neoplasms
The HIV protease inhibitor saquinavir induces endoplasmic reticulum stress, autophagy, and apoptosis in ovarian cancer cells.
Pancreatic Neoplasms
ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer.
Pancreatic Neoplasms
Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer.
Papilloma
Raman chemical mapping reveals site of action of HIV protease inhibitors in HPV16 E6 expressing cervical carcinoma cells.
Papilloma
The Impact of Human Papilloma Viruses, Matrix Metallo-Proteinases and HIV Protease Inhibitors on the Onset and Progression of Uterine Cervix Epithelial Tumors: A Review of Preclinical and Clinical Studies.
Paraparesis, Tropical Spastic
Design of potent aspartic protease inhibitors to treat various diseases.
Parasitemia
Prevalence of Asymptomatic Parasitemia and Gametocytemia in HIV-Infected Children on Differing Antiretroviral Therapy.
Parasitic Diseases
HIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites.
Peripheral Nervous System Diseases
A rodent model of HIV protease inhibitor indinavir induced peripheral neuropathy.
Peripheral Nervous System Diseases
Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy.
Persistent Infection
Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis.
Persistent Infection
Preclinical evaluation of antiviral activity and toxicity of Abbott A77003, an inhibitor of the human immunodeficiency virus type 1 protease.
Persistent Infection
Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.
Pneumocystis Infections
Detection of HIV protease inhibitors in alveolar epithelial lining fluid: relevance for modulation of pneumocystis infection in the course of HAART.
Prostatic Neoplasms
HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling.
Prostatic Neoplasms
HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo.
Prostatic Neoplasms
The HIV protease and PI3K/Akt inhibitor nelfinavir does not improve the curative effect of fractionated irradiation in PC-3 prostate cancer in vitro and in vivo.
Proteinuria
Plasma Nitration of High-Density and Low-Density Lipoproteins in Chronic Kidney Disease Patients Receiving Kidney Transplants.
Pulmonary Arterial Hypertension
Nordihydroguaiaretic acid (NDGA) inhibits ritonavir-induced endothelial dysfunction in porcine pulmonary arteries.
Rectal Neoplasms
Everything Old Is New Again: Using Nelfinavir to Radiosensitize Rectal Cancer.
Retinitis
Cicatrization of cytomegalovirus retinitis following introduction of highly active anti-retroviral therapy: uveitis as a possible indicator of good ocular prognosis.
Retinitis
[Incidence and evaluation of viral retinitis in patients infected with the HIV virus and treated with HIV protease inhibitors]
Sarcoma
Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis.
Sarcoma, Avian
Cleavage of the X-Pro peptide bond by pepsin is specific for the trans isomer.
Sarcoma, Avian
Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease.
Sarcoma, Avian
Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.
Sarcoma, Avian
X-ray analysis of HIV-1 proteinase at 2.7 A resolution confirms structural homology among retroviral enzymes.
Sarcoma, Kaposi
Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma.
Sarcoma, Kaposi
Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir.
Sarcoma, Kaposi
Combined radiation sensitizing and anti-angiogenic effects of ionizing radiation and the protease inhibitor ritonavir in a head and neck carcinoma model.
Sarcoma, Kaposi
Evaluation of antitumoral properties of the protease inhibitor indinavir in a murine model of hepatocarcinoma.
Sarcoma, Kaposi
HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma.
Sarcoma, Kaposi
HIV-protease inhibitors for the treatment of cancer: Repositioning HIV protease inhibitors while developing more potent NO-hybridized derivatives?
Sarcoma, Kaposi
Regression of AIDS-related Kaposi's sarcoma following treatment with an HIV-1 protease inhibitor.
Sarcoma, Kaposi
Regression of Kaposi's sarcoma during therapy with HIV-1 protease inhibitors: a prospective pilot study.
Sarcoma, Kaposi
Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth.
Severe Acute Respiratory Syndrome
Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment.
Shoulder Pain
Adhesive capsulitis of shoulder and treatment with protease inhibitors in patients with human immunodeficiency virus infection: report of 8 cases.
Spinal Cord Diseases
Design of potent aspartic protease inhibitors to treat various diseases.
Squamous Cell Carcinoma of Head and Neck
HIV Protease Inhibitors Sensitize Human Head and Neck Squamous Carcinoma Cells to Radiation by Activating Endoplasmic Reticulum Stress.
Stroke
Evaluation of HIV protease inhibitor use and the risk of sudden death or nonhemorrhagic stroke.
Superinfection
Lack of detectable human immunodeficiency virus type 1 superinfection during 1072 person-years of observation.
Thrombocytopenia
Acute thrombocytopenia secondary to the administration of the peptidomimetic HIV protease inhibitor MK-639(L735524)
Thrombosis
Portal vein thrombosis in patients receiving indinavir, an HIV protease inhibitor.
Thyroid Neoplasms
Nelfinavir inhibits proliferation and induces DNA damage in thyroid cancer cells.
Thyroid Neoplasms
The HIV Protease Inhibitor Nelfinavir Dowregulates RET Signaling and Induces Apoptosis in Medullary Thyroid Cancer Cells.
Torsades de Pointes
Inhibition of cytochrome P450 3A: relevant drug interactions in gastroenterology.
Torsades de Pointes
The protease inhibitor atazanavir blocks hERG K(+) channels expressed in HEK293 cells and obstructs hERG protein transport to cell membrane.
Tuberculosis
Clinical update: impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin.
Tuberculosis
Effect of HIV protease inhibitors and Orlistat on mycobacterial ES-31 serine protease, a potential drug target in Mycobacterium tuberculosis.
Tuberculosis
Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers.
Tuberculosis
From the Centers for Disease Control and Prevention. Clinical update: impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin.
Tuberculosis
Pharmacokinetics of rifabutin during atazanavir/ritonavir co-administration in HIV-infected TB patients.
Tuberculosis
Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy.
Urolithiasis
Atazanavir-Induced Urine Crystals Demonstrated by Infrared Spectroscopic Analysis.
Urolithiasis
Nonopaque crystal deposition causing ureteric obstruction in patients with HIV undergoing indinavir therapy.
Urologic Neoplasms
Lopinavir-Ritonavir Combination Induces Endoplasmic Reticulum Stress and Kills Urological Cancer Cells.
Uterine Cervical Neoplasms
Bortezomib Targets the Caspase-Like Proteasome Activity in Cervical Cancer Cells, Triggering Apoptosis That Can be Enhanced by Nelfinavir.
Uterine Cervical Neoplasms
HIV protease inhibitors to prevent progression of cervical intraepithelial neoplasia to cervical cancer: therapeutic opportunities and challenges.
Uterine Cervical Neoplasms
Nelfinavir, an HIV protease inhibitor, induces apoptosis and cell cycle arrest in human cervical cancer cells via the ROS-dependent mitochondrial pathway.
Uveitis
Cicatrization of cytomegalovirus retinitis following introduction of highly active anti-retroviral therapy: uveitis as a possible indicator of good ocular prognosis.
Vascular Diseases
Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction.
Vascular System Injuries
The soybean isoflavonoid equol blocks ritonavir-induced endothelial dysfunction in porcine pulmonary arteries and human pulmonary artery endothelial cells.
Viremia
Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads.
Virus Diseases
Catalytic efficiency and phenotype of HIV-1 proteases encoding single critical resistance substitutions.
Virus Diseases
Effect of human immunodeficiency virus type 1 protease on the intermediate filament subunit protein vimentin: cleavage, in vitro assembly and altered distribution of filaments in vivo following microinjection of protease.
Virus Diseases
Efficacy of local budesonide therapy in the management of persistent hyposmia in COVID-19 patients without signs of severity: A structured summary of a study protocol for a randomised controlled trial.
Virus Diseases
Mitochondrial membrane hyperpolarization hijacks activated T lymphocytes toward the apoptotic-prone phenotype: homeostatic mechanisms of HIV protease inhibitors.
Virus Diseases
Non-infectious in-cell HIV-1 protease assay utilizing translocalization of a fluorescent reporter protein and apoptosis induction.
Virus Diseases
Noninvasive high-throughput single-cell analysis of HIV protease activity using ratiometric flow cytometry.
Virus Diseases
Peptide inhibitors of HIV-1 protease and viral infection of peripheral blood lymphocytes based on HIV-1 Vif.
Virus Diseases
Simultaneous assay for protease activities of hepatitis C virus and human immunodeficiency virus based on fluorescence detection.
Virus Diseases
Successful sofosbuvir lead-in monotherapy for the treatment of hepatitis C virus (HCV) infection in a pregnant woman living with HIV.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.00000039
amprenavir
wild type enzyme, at pH 5.0 and 20°C
0.000001
amprenavir
mutant enzyme V32I/I47V/V82I, at pH 4.0 and 28°C
0.0000035
amprenavir
mutant enzyme V32I/I47V/V82I, at pH 5.8 and 28°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
physiological function
the enzyme is essential to the replication and invasion of HIV and is responsible for cleaving large polyprotein precursors Gag and releasing small structural proteins to help the assembly of infectious viral particles
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable).
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PDB
SCOP
CATH
UNIPROT
ORGANISM
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CRYSTALLIZATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
hanging drop vapor diffusion method, using 0.25 M sodium citrate pH 6.0, 10% (v/v) DMSO, and 40%-60% (w/v) saturated ammonium sulfate
mutant enzyme V32I/I47V/V82I in complex with amprenavir, sitting drop vapor diffusion method, using 0.1M MES, 0.9 M NaCl, pH 6.0 in H2O
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
D29N
the mutation can largely reduce the binding capability of the two peptides ARVLAEAM and NLAFPQGE as compared to the wild type enzyme
I54V
the mutant enzyme is resistant against inhibition by darunavir and nelfinavir
L10I
the mutant enzyme is resistant against inhibition by darunavir and tipranavir
L90M
the mutant enzyme is resistant against inhibition by darunavir and tipranavir
M46L
the mutant enzyme is resistant against inhibition by darunavir and saquinavir
N25D
the mutation completely eliminates the binding capability of the two peptides ARVLAEAM and NLAFPQGE as compared to the wild type enzyme
V32I/I47V/V82I
the three mutations do not significantly alter the interaction between inhibitor amprenavir and the enzyme
V82T
the mutant enzyme is resistant against inhibition by darunavir
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PURIFICATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
high performance liquid chromatography and gel filtration
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
expressed in Escherichia coli BL21-Gold (DE3)pLysS cells
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Gerlits, O.; Keen, D.A.; Blakeley, M.P.; Louis, J.M.; Weber, I.T.; Kovalevsky, A.
Room temperature neutron crystallography of drug resistant HIV-1 protease uncovers limitations of X-ray structural analysis at 100 K
J. Med. Chem.
60
2018-2025
2017
Human immunodeficiency virus 1 (Q7SSI0), Human immunodeficiency virus 1
brenda
Lv, Y.; Li, J.; Fang, J.; Jiao, X.; Yan, L.; Shan, B.
Systematic profiling of substrate binding response to multidrug-resistant mutations in HIV-1 protease Implication for combating drug resistance
J. Mol. Graph. Model.
74
83-88
2017
Human immunodeficiency virus 1 (Q7SSI0), Human immunodeficiency virus 1
brenda
Olajuyigbe, F.M.; Demitri, N.; De Zorzi, R.; Geremia, S.
Developing HIV-1 protease inhibitors through stereospecific reactions in protein crystals
Molecules
21
1458
2016
Human immunodeficiency virus 1 (Q7SSI0), Human immunodeficiency virus 1
brenda
Yu, Y.; Wang, J.; Shao, Q.; Shi, J.; Zhu, W.
Effects of drug-resistant mutations on the dynamic properties of HIV-1 protease and inhibition by amprenavir and darunavir
Sci. Rep.
5
10517
2015
Human immunodeficiency virus 1 (Q7SSI0), Human immunodeficiency virus 1
brenda
EXTERNAL LINKS (specific for EC-Number 3.4.23.16)
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
About BRENDA
Social media
Help
Survey
Download
Contribution
Legal
Curated at
Member of
